Your session is about to expire
← Back to Search
Xanthine Oxidase Inhibitor
D-0120 plus Allopurinol for Healthy Subjects
Phase < 1
Waitlist Available
Research Sponsored by InventisBio Co., Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Healthy subjects between the ages of 18-55
Required evaluation by Investigator for screening and enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days
Awards & highlights
Study Summary
Evaluation of safety and PK interaction between D-0120 and Alopurinol in healthy adult subjects
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 14 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Plasma concentration of D-0120 and Allopurinol
Type, incidence, severity and attribution of AEs.
Side effects data
From 2019 Phase 3 trial • 530 Patients • NCT0201717116%
Rash
12%
Upper respiratory tract infection
10%
Hypoglycaemia
7%
Nasopharyngitis
6%
Diabetic ketoacidosis
6%
Influenza like illness
6%
Sinusitis
6%
Urinary tract infection
5%
Pain in extremity
4%
Bronchitis
3%
Acute myocardial infarction
2%
Osteomyelitis
2%
Abortion spontaneous
1%
Renal failure acute
1%
Hyperglycaemia
1%
Hyperemesis gravidarum
1%
Pregnancy
1%
Asthma
1%
Cellulitis
1%
Angina unstable
1%
Diarrhoea
1%
Gastrointestinal haemorrhage
1%
Pneumonia
1%
Myocardial infarction
1%
Cardiac arrest
1%
Cardiac failure congestive
1%
Coronary artery disease
1%
Impaired gastric emptying
1%
Pancreatitis acute
1%
Chest pain
1%
Death
1%
Staphylococcal infection
1%
Cerebrovascular accident
1%
Skin ulcer
1%
Amputation
1%
Road traffic accident
1%
Diabetic gastroparesis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Allopurinol
Placebo
Trial Design
2Treatment groups
Experimental Treatment
Group I: D-0120 plus AllopurinolExperimental Treatment1 Intervention
D-0120 dosing followed by Allopurinol and combination treatment
Group II: Allopurinol plus D-0120Experimental Treatment1 Intervention
Allopurinol dosing followed by D-0120 and combination treatment
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Allopurinol
FDA approved
Find a Location
Who is running the clinical trial?
InventisBio Co., LtdLead Sponsor
19 Previous Clinical Trials
1,935 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger